- In August 2023, a review of Phase II and III trials highlighted the emergence of new drugs for dementia with Lewy bodies (DLB). Despite DLB being associated with faster cognitive decline and having a greater negative impact on patients and caregivers compared to Alzheimer's disease (AD), drug development efforts for DLB lag behind those for AD. Currently, off-label drug options for DLB are limited to symptomatic agents developed for addressing cognitive deficits in AD, motor deficits in Parkinson's disease, or behavioral symptoms in psychiatric diseases. However, recent improvements in DLB diagnosis have sparked a new focus on the development of disease-modifying agents (DMA) for DLB
- In October 2022, Pfizer Inc., a multinational pharmaceutical and biotechnology corporation, completed the acquisition of Biohaven Pharmaceuticals Inc. for USD 11.6 billion. This strategic move is intended to bolster Pfizer's ability to provide innovative treatment solutions worldwide. Biohaven Pharmaceuticals Inc. is dedicated to developing pharmaceuticals for Parkinson's disease, a condition associated with Lewy body dementia, aligning with Pfizer's goal to expand its portfolio of therapies in this therapeutic area
